Source-grounded facts extracted from Edwards Lifesciences Corp's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Edwards Lifesciences Corp shareholders approved Approval of the Company’s Amended and Restated Long-Term Stock Incentive Compensation Program at the 2026-05-07 meeting.
“Proposal 4 : The approval of the Company’s Amended and Restated Long-Term Stock Incentive Compensation Program was approved as set forth below: For Against Abstain Broker Non-Votes 456,675,201 19,210,539 0 27,211,476”
Edwards Lifesciences Corp shareholders approved Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-05-07 meeting.
“Proposal 3 : Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was approved as set forth below: For Against Abstain Broker Non-Votes 446,283,142 56,814,075 0 27,211,476”
Edwards Lifesciences Corp shareholders approved Advisory proposal regarding the Company’s named executive officer compensation at the 2026-05-07 meeting.
“Proposal 2 : The advisory proposal regarding the Company’s named executive officer compensation was approved as set forth below: For Against Abstain Broker Non-Votes 424,961,639 50,924,101 0 27,211,476”
Edwards Lifesciences Corp shareholders approved Election of nine directors at the 2026-05-07 meeting.
“Proposal 1 : All the nominees for director listed in Proposal 1 were elected to serve until the Company’s next annual meeting of stockholders and until their respective successors are duly elected and qualified as set forth below: Nominee For Against Abstain Broker Non-Votes Leslie C. Davis 461,819,765 13,184,241 881,733 27,211,476 David T. Feinberg, MD 473,746,144 1,812,520 327,076 27,211,476 Kieran T. Gallahue 457,045,403 18,518,195 322,142 27,211,476 Leslie S. Heisz 454,955,195 20,567,869 362,676 27,211,476 Paul A. LaViolette 428,701,646 45,445,276 1,738,817 27,211,476 Steven R. Loranger 446,216,434 28,909,945 759,361 27,211,476 Ramona Sequeira 474,260,552 1,295,682 329,506 27,211,476 Nicholas J. Valeriani 441,224,095 34,327,820 333,825 27,211,476 Bernard J. Zovighian 459,179,727 16,257,009 449,004 27,211,476”
Theodora Mistras was appointed as Corporate Vice President, Chief Financial Officer at Edwards Lifesciences Corp.
“On May 4, 2026, Edwards Lifesciences Corporation, a Delaware corporation (the “Company”), announced that Theodora Mistras has been appointed as the Corporate Vice President, Chief Financial Officer of the Company, effective May 29, 2026, to succeed Scott B. Ullem in that position.”
Edwards Lifesciences Corp updated its first quarter of 2026 guidance (raised).
“issued a press release setting forth Edwards' financial results for the first quarter of 2026.”
David T. Feinberg was appointed as Director at Edwards Lifesciences Corp.
“On July 10, 2024, Edwards Lifesciences Corporation, a Delaware corporation (the “Company”), appointed David T. Feinberg, M.D. to the Company’s Board of Directors (the “Board”), effective immediately.”
Andrew M. Dahl was appointed as Principal Accounting Officer at Edwards Lifesciences Corp.
“On the Retirement Date, Mr. Sellers will be succeeded by Andrew M. Dahl, currently Senior Vice President and Corporate Controller of the Company.”
Robert W.A. Sellers departed as Senior Vice President, Principal Accounting Officer at Edwards Lifesciences Corp.
“Robert W.A. Sellers, Senior Vice President, Principal Accounting Officer of the Company, of his decision to retire, effective as of July 1, 2024”
Edwards Lifesciences Corp shareholders approved The approval of the Company’s Amended and Restated Long-Term Stock Incentive Compensation Program at the 2024-05-07 meeting.
“Proposal 4 : The approval of the Company’s Amended and Restated Long-Term Stock Incentive Compensation Program was approved as set forth below:”
Edwards Lifesciences Corp shareholders approved Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 at the 2024-05-07 meeting.
“Proposal 3 : Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 was approved as set forth below:”
Edwards Lifesciences Corp shareholders approved Advisory proposal regarding the Company’s named executive officer compensation at the 2024-05-07 meeting.
“Proposal 2 : The advisory proposal regarding the Company’s named executive officer compensation was approved as set forth below:”
Edwards Lifesciences Corp shareholders approved Election of Directors at the 2024-05-07 meeting.
“All the nominees for director listed in Proposal 1 were elected to serve until the Company’s next annual meeting of stockholders and until their respective successors are duly elected and qualified as set forth below:”
Martha H. Marsh departed as director at Edwards Lifesciences Corp.
“Martha H. Marsh has reached the retirement age set forth in the Company’s Corporate Governance Guidelines and will therefore not be nominated to stand for election to the Board at the 2024 Annual Meeting.”
Nicholas J. Valeriani was appointed as Chairman of the Board at Edwards Lifesciences Corp.
“The Company expects to appoint Nicholas J. Valeriani, an independent director, to succeed Mr. Mussallem as Chairman of the Board.”
Michael A. Mussallem departed as Non-Executive Chairman at Edwards Lifesciences Corp.
“Michael A. Mussallem informed the Board of Directors (the Board) of his decision to retire as Non-Executive Chairman and a director of the Board which will be effective in conjunction with the Company’s annual meeting of stockholders on May 7, 2024”
Edwards Lifesciences Corp reported the year ended December 31, 2023 results: revenue $6.0 billion, EPS $2.30.
“Sales for the year ended December 31, 2023, were $6.0 billion, a year-over-year increase of 12 percent on both a reported and constant currency basis. Diluted earnings per share for 2023 were $2.30, while adjusted earnings per share were $2.51 .”
Edwards Lifesciences Corp reported the quarter ended December 31, 2023 results: revenue $1.53 billion, EPS $0.61.
“Feb. 6, 2024 — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended December 31, 2023. Highlights and Outlook • Q4 sales grew 14 percent to $1.53 billion; constant currency 1 sales grew 13 percent • Q4 TAVR sales grew 13 percent; constant currency sales grew 12 percent • Q4 EPS of $0.61; adjusted 1 EPS of $0.64 • 2023 sales of”
Edwards Lifesciences Corp reported the quarter ended Sept. 30, 2023 results: revenue $1.48 billion, EPS $0.63. Guidance reaffirmed.
“25, 2023 — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Sept. 30, 2023. Recent Highlights and Outlook • Q3 sales grew 12 percent to $1.48 billion; constant currency 1 sales grew 11 percent • Q3 TAVR sales grew 11 percent; constant currency sales grew 10 percent • Q3 EPS of $0.63; adjusted 1 EPS of $0.59 • Received CE Mark”
Edwards Lifesciences Corp updated its second quarter of 2023 guidance (raised).
“On July 26, 2023, Edwards Lifesciences Corporation, a Delaware corporation (“Edwards”), issued a press release setting forth Edwards’ financial results for the second quarter of 2023.”
Edwards Lifesciences Corp: Amendment to Certificate of Incorporation to provide for exculpation of officers as permitted by the Delaware General Corporation Law (effective 2023-05-12).
“On May 11, 2023, the Company held its 2023 Annual Meeting of Stockholders (the “Annual Meeting”), at which stockholders approved an amendment (the “Amendment”) to the Company’s Amended and Restated Certificate of Incorporation to provide for exculpation of officers as permitted by the Delaware General Corporation Law. The Amendment became effective immediately upon filing with the Secretary of State of the State of Delaware on May 12, 2023.”
Edwards Lifesciences Corp shareholders rejected Proposal 6: Stockholder proposal regarding independent board chairman policy at the 2023-05-11 meeting.
“The stockholder proposal regarding an independent board chairman policy was not approved”
Edwards Lifesciences Corp shareholders approved Proposal 5: Amendment to Certificate of Incorporation for officer exculpation at the 2023-05-11 meeting.
“The amendment of the Company’s Certificate of Incorporation to provide for exculpation of officers as permitted by the Delaware General Corporation Law was approved”
Edwards Lifesciences Corp shareholders approved Proposal 4: Ratification of PricewaterhouseCoopers LLP as independent auditor for 2023 at the 2023-05-11 meeting.
“Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was approved”
Edwards Lifesciences Corp shareholders approved Proposal 3: Advisory vote on frequency of future say-on-pay votes at the 2023-05-11 meeting.
“The advisory proposal regarding the frequency of advisory votes on named executive officer compensation was approved with one year as the preferred frequency”
Edwards Lifesciences Corp shareholders approved Proposal 2: Advisory vote on named executive officer compensation at the 2023-05-11 meeting.
“The advisory proposal regarding the Company’s named executive officer compensation was approved”
Edwards Lifesciences Corp shareholders approved Proposal 1: Election of Directors at the 2023-05-11 meeting.
“All the nominees for director listed in Proposal 1 were elected to serve until the Company’s next annual meeting of stockholders and until their respective successors are duly elected and qualified”
Edwards Lifesciences Corp reported the quarter ended March 31, 2023 results: revenue $1.46 billion, EPS $0.56. Guidance raised.
“April 26, 2023 — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended March 31, 2023. Highlights and Outlook • Q1 sales grew 9 percent to $1.46 billion; constant currency 1 sales grew 13 percent • Q1 TAVR sales grew 8 percent; constant currency sales grew 11 percent • Q1 EPS of $0.56; adjusted 1 EPS of $0.62 • Repurchased”
Edwards Lifesciences Corp: Amended and restated Bylaws to incorporate universal proxy rule (Rule 14a-19) and update advance notice provisions for director nominations, including new disclosure and compliance requirements (effective 2023-02-16).
“On February 16, 2023, the Board of Directors (the “Board”) of Edwards Lifesciences Corporation, a Delaware corporation (the “Company”), amended and restated the Company’s Bylaws (as so amended and restated, the “Bylaws”).”
Edwards Lifesciences Corp reported first quarter of 2023 results: revenue $1.37 to $1.45 billion, EPS $0.58 to $0.64. Guidance initiated.
“For the first quarter of 2023, the company projects total sales to be between $1.37 and $1.45 billion, and adjusted EPS of $0.58 to $0.64.”
Edwards Lifesciences Corp reported full year 2023 results: revenue $5.6 to $6.0 billion, EPS $2.45 to $2.60. Guidance reaffirmed.
“Overall, the company is reaffirming the sales guidance it provided at the December investor conference for all product groups. Full year 2023 sales are expected to grow 9 to 12 percent to $5.6 to $6.0 billion. Additionally, the company continues to expect full year 2023 adjusted earnings per share of $2.45 to $2.60.”
Edwards Lifesciences Corp reported year ended December 31, 2022 results: revenue $5.38 billion, EPS $2.44.
“Sales for the year ended December 31, 2022, were $5.38 billion, a year-over-year increase of 3 percent, or 8 percent on an underlying basis. Although initial sales expectations for 2022 anticipated a better healthcare environment, the company delivered balanced contributions across each of its product groups and regions. Diluted earnings per share for 2022 were $2.44, while adjusted earnings per share of $2.48 increased 12 percent from the year-ago period.”
Edwards Lifesciences Corp reported quarter ended December 31, 2022 results: revenue $1.35 billion, EPS $0.65.
“Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended December 31, 2022. Highlights and Outlook • Q4 sales grew 1 percent to $1.35 billion; constant currency 1 sales grew 7 percent • Q4 TAVR sales were flat; constant currency sales grew 5 percent • Q4 EPS of $0.65; adjusted 1 EPS increased 25 percent to $0.64”
Larry Wood was appointed as Corporate Vice President and Group President at Edwards Lifesciences Corp.
“the Board’s appointment of Larry Wood to an expanded role as corporate vice president and group president, Transcatheter Aortic Valve Replacement and Surgical Structural Heart effective January 1, 2023”
Bernard J. Zovighian was appointed as Chief Executive Officer at Edwards Lifesciences Corp.
“At the 2023 Annual Meeting, Mr. Mussallem will be succeeded as CEO by Bernard J. Zovighian, currently corporate vice president and general manager for Edwards’ Transcatheter Mitral and Tricuspid Therapies (“TMTT”) business.”
Bernard J. Zovighian was appointed as President at Edwards Lifesciences Corp.
“On December 6, 2022 the Board appointed Bernard J. Zovighian as President of the Company, effective January 1, 2023, until he becomes CEO on May 11, 2023.”
Michael A. Mussallem retired as Non-executive Chairman at Edwards Lifesciences Corp.
“On December 6, 2022, Michael A. Mussallem informed the Board of Directors (the “Board”) of Edwards Lifesciences Corporation, a Delaware corporation (“Edwards” or the “Company”), of his decision to retire as Chief Executive Officer of Edwards in connection with Edwards’ Annual Meeting of Stockholders on May 11, 2023.”
Edwards Lifesciences Corp updated its quarter ended September 30, 2022 guidance (lowered).
“On October 27, 2022, Edwards Lifesciences Corporation, a Delaware corporation (“Edwards”), issued a press release setting forth Edwards’ financial results for the third quarter of 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.